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GABAA receptors (GABAARs) exist as different subtype variants showing unique functional 
properties  and  defined  spatio-temporal  expression  pattern.  The  molecular  mechanisms 
underlying  the  developmental  expression  of  different  GABAAR  are  largely  unknown.  The 
intracellular concentration of chloride ([Cl − ]i), the main ion permeating through GABAARs, 
also undergoes considerable changes during maturation, being higher at early neuronal stages 
with respect to adult neurons. Here we investigate the possibility that [Cl − ]i could modulate the 
sequential expression of specific GABAARs subtypes in primary cerebellar neurons. We show 
that [Cl − ]i regulates the expression of α3-1 and δ-containing GABAA receptors, responsible for 
phasic and tonic inhibition, respectively. our findings highlight the role of [Cl − ]i in tuning the 
strength of GABAergic responses by acting as an intracellular messenger. 
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T
he  GABAergic  system  undergoes  profound  developmental 
changes.  Most  remarkably,  during  development,  GABAA 
action  shifts  from  depolarizing  to  hyperpolarizing1.  The 
polarity of GABA responses depends upon the intracellular chloride 
concentration ([Cl − ]i), which is mainly controlled by the action of 
Na + -K + -2Cl −  (NKCC1) and K + -Cl −  (KCC2) co-transporters. In 
the immature brain, NKCC1 expression determines high [Cl − ]i, 
promoting depolarizing GABA responses which has been demon-
strated to lead to excitation by promoting sodium action potential 
triggering, voltage-gated calcium channel activation and generation 
of giant depolarizing potentials2,3. In addition, depolarizing GABA 
action can also lead to inhibition due to the presence of shunting 
inhibition that, in turn, critically depends on the chloride driving 
force and the synapse location4,5. In contrast, in the adult brain, 
chloride extrusion operated by KCC2 establishes low [Cl − ]i, with   
consequent  inhibitory  action  of  GABAAergic  currents.  Such 
developmental  chloride  gradient  inversion  is  assumed  to  occur 
in all neurons of the central nervous system (CNS), although its   
timing can significantly vary in various brain regions and neuro-
nal subtypes 1,6,7. In addition to the [Cl − ]i changes, the expression 
of  distinct  post-synaptic  GABAA  receptor  (GABAAR)  subtypes 
also  undergoes  developmental  regulation8.  In  the  cerebellum, 
immature  GABAergic  synapses  express  α3-containing  GABAAR 
that  are  progressively  replaced  by  α1-containing  receptors  at 
mature synapses9,10. Such GABAAR-subtype switch underlies the 
developmental speed-up from the slow decay kinetics of α3-con-
taining  GABAARs  to  the  fast  decay  kinetics  of  α1-containing 
GABAARs9,10,11. It is believed that long-lasting α3-mediated cur-
rents promote trophic actions in immature neurons, whereas fast 
α1-mediated hyperpolarizing spontaneous inhibitory postsynaptic 
currents (sIPSCs) contribute to increase the network temporal reso-
lution in mature neurons9,10,12. Moreover, tonic current has been 
shown to increase over development in cerebellar acute slices due 
to the progressive expression of the δ subunit10,13. The molecular 
mechanisms underlying the developmental α3 to α1 switch and δ 
subunit up-regulation are poorly understood. Since the shift in the 
polarity of chloride gradient occurs in parallel with the α3 to α1 
GABAAR subunit switch during the first two postnatal weeks, in 
this study we investigated whether changes in [Cl − ]i interfere with 
the surface expression of α3 and α1 subunits by using a genetic and 
pharmacological  approach.  Electrophysiological  and  immunocy-
tochemistry  results  demonstrated  that  the  intracellular  chloride 
concentration regulates the expression of α3-α1 and δ subunits of 
GABAARs, thereby influencing both the kinetics of sIPSCs and the 
amount of tonic inhibition.
Results
a3-1  and  d  subunits  are  affected  by  KCC2  or  Bumetanide. 
To  investigate  the  role  of  [Cl − ]i  in  the  regulation  of  α  and  δ 
subunit expression of GABAARs, we studied the decay kinetics of 
spontaneous GABAAergic currents and the expression of α3/α1 
subunits  in  cerebellar  neurons  (stellate/basket  cells,  Methods). 
To this end, in a first set of experiments, the [Cl − ]i was reduced 
by over-expression of KCC2 in immature neurons on the day of 
the  plating  (Fig.  1a).  As  expected,  gramicidin  perforated  patch-
clamp  experiments  revealed  that,  in  cultures  at  days  in  vitro 
6–7  (DIV6–7),  the  reduced  [Cl − ]i  resulting  from  KCC2  over-
expression  reverted  GABAA  current  polarity  from  depolarizing 
to  hyperpolarizing  responses  (ECl:   − 38 ± 4  and   − 64 ± 7 mV  in 
control and KCC2 over-expression, respectively, P < 0.01 unpaired 
t-test,  Vm:  55.0 ± 3.4 mV;  Fig.  2a–c).  Notably,  these  data  were 
corroborated by immunocytochemistry showing an increased KCC2 
immunoreactivity  in  KCC2  over-expressing  neurons  at  DIV6–7   
(Fig. 2d,e). The GABAergic sIPSCs from DIV6–7 was recorded under 
over-expression  of  KCC2.  Interestingly,  KCC2  over-expression 
accelerated  the  relaxation  of  sIPSCs,  leaving  unchanged  their 
frequency (Fig. 2f–h) and did not affect the density of GABAergic 
synapses as confirmed by VGAT immunostaining (Fig. 2i,j). Since 
the  GABAAR-mediated  tonic  current  is  also  developmentally 
regulated  in  acute  slices,  being  small  in  immature  neurons  and 
progressively  larger  during  development10,13,  we  investigated 
whether it was also affected in KCC2 over-expressing neurons. As 
shown in Fig. 2k, DIV6–7 neurons over-expressing KCC2 displayed 
larger tonic current amplitude than untreated neurons. This set of 
data supports the hypothesis that over-expression of KCC2 might 
influence the expression of α3/α1 and δ GABAAR subunits, crucial 
for both the kinetics of synaptic currents and the amplitude of tonic 
GABA current, respectively. To further demonstrate this hypothesis, 
the relative amount of GABAAR α3, α1 and δ subunits in neurons 
with low [Cl − ]i was studied by immunocytochemistry. As shown in   
Fig.  2l,m  KCC2  over-expression  in  DIV6–7  neurons  led  to  an 
increase in the expression of α1 subunit, whereas the α3 subunit was 
expressed to a lower extent in comparison to controls. In a second 
set of immunocytochemistry experiments, we observed that the   
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Figure 1 | Summary of experimental procedures timing for the 
genetic and pharmacological approches. (a) In KCC2 over-expression 
experiments, transfection was performed at DIV0 whereas the recordings 
of IPsCs, ECl measurements and immunocytochemistry (IC) were 
performed at DIV 6–7. (b) In chronic Bumetanide experiments, the drug 
was applied at DIV0 whereas the recordings of IPsCs, ECl measurements 
and immunocytochemistry (IC) were performed at DIV 6–7. (c) In KCC2 
shRnA experiments, transfection was performed at DIV5 whereas the 
recordings of IPsCs, ECl measurements and immunocytochemistry (IC) 
were performed at DIV12–13. (d) In chronic DIoA experiments, the drug 
was applied at DIV5 whereas the recordings of IPsCs, ECl measurements 
and immunocytochemistry (IC) were performed at DIV 12–13. (e) In late 
transfection of KCC2 shRnA experiments, trasfection was performed at 
DIV12–13 whereas the recordings of IPsCs and immunocytochemistry (IC) 
were performed at DIV14.ARTICLE     
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surface expression of δ subunit was also increased in KCC2 over-
expressing neurons at DIV 6–7 (Fig. 2n,o). Taken together, these 
data corroborate the electrophysiological results, and suggest that 
the developmental expression of GABAAR α3 − α1 and δ subunits 
is regulated by KCC2 expression.
In the previous set of experiments, the [Cl − ]i was modified by 
up-regulating KCC2 protein. However, it has been shown that KCC2 
is abundant at glutamatergic synapses14, where it acts by binding 
to cytoskeletal elements, to promote dendritic spine maturation15 
in a manner independent of its transporter function. To rule out 
the possibility that changes in sIPSC characteristics and GABAAR 
subunit expression result from an alteration of the structural role 
of KCC2, the [Cl − ]i was modified by chronically treating neurons 
with Bumetanide, a pharmacological agent that blocks the activ-
ity of NKCC1. Cerebellar cultures were treated for one week with 
Bumetanide (30 µM) starting on DIV0 (Fig. 1b) to replicate the tim-
ing used with KCC2 over-expression. To assess the effect of Bumeta-
nide on the [Cl − ]i under our experimental conditions we measured 
ECl in gramicidin-perforated patch in immature cultures in pres-
ence of Bumetanide. As expected, in DIV6–7 cultures, Bumetanide 
treatment induced a significant shift of ECl toward more hyper-
polarized  values  ( − 49.25 ± 3.47  and   − 62.67 ± 5.8 mV  in  control 
and Bumetanide, respectively; P < 0.05 unpaired t-test; Fig. 3a–c). 
Next, we studied the effect of chronic treatment with Bumetanide 
on GABAergic sIPSCs. In DIV6–7, this drug significantly acceler-
ated the sIPSC decay kinetics (τmean = 31.2 ± 1.7 and 18.9 ± 0.8 ms 
in control and Bumetanide, respectively; P < 0.001 unpaired t-test), 
without  affecting  the  sIPSC  frequency  (Fig.  3d–f).  In  addition, 
chronic  Bumetanide  treatment  also  increased  the  amplitude  of 
tonic current at DIV6–7 (Fig. 3g). In analogy with the experiments 
performed with altered KCC2 expression, we next investigated the 
expression levels of α3 − α1 and δ subunits in neurons chronically 
treated with Bumetanide. In DIV6–7 cultures, Bumetanide treat-
ment reduced the expression of α3 subunit, while it increased the 
expression of both α1 and δ subunits with respect to control values   
(Fig.  3h–k).  These  immunocytochemical  data  are  in  agreement 
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Figure 2 | KCC2 over-expression affects GABAergic currents and regulates the expression of a3-a1 and d subunits. (a) Example of I–V relations of 
isoguvacine (10 µm) evoked GABAA currents at increasing holding potentials in control neurons. (b) Example of I–V relations of isoguvacine (10 µm) 
evoked GABAA currents at increasing holding potentials in KCC2 over-expressing neurons. (c) Bar plot showing the mean ECl in immature neurons 
(control, grey bar n = 6; KCC2 over, black bar n = 7; **P < 0.01; unpaired t-test). (d) somatic KCC2 immunostaining in control and KCC2 over-expressing 
neuron. (scale bar: 5 µm). (e) Quantification of KCC2 immunofluorescence signals in control and KCC2 transfected neurons (control, grey bar n = 16; 
KCC2 over, black bar n = 20; ***P < 0.001; unpaired t-test). (f) Representative sIPsCs from control and KCC2 transfected neurons. (g) summary of sIPsC 
decay kinetics in control (grey bar n = 44) and KCC2 transfected neurons (black bar n = 37; **P < 0.01; unpaired t-test). (h) summary of sIPsC frequency 
in control (grey bar n = 41) and KCC2 transfected neurons (black bar n = 40; P > 0.05; unpaired t-test). (i) Immunostaining of VGAT clusters (green 
fluorescence) in control (left panel) and KCC2 over-expressing neurons (right panel). (j) summary of VGAT cluster density quantification in control (grey 
bar n = 19) and KCC2 transfected neurons (black bar n = 24; P > 0.05; unpaired t-test). (k) summary of tonic current amplitude in control (grey bar n = 43) 
and KCC2 neurons (black bar n = 28; *P < 0.05; unpaired t-test). (l) somatic immunostaining of immunofluorescence signals for α3 and α1 subunits in 
control and KCC2 over-expressed neurons at DIV7, scale bar 10 µm. (m) Quantification of immunofluorescence signals for α3 and α1 subunits at DIV7 
(α3 control, grey bar n = 69; KCC2 over, black bar n = 75; **P < 0.01; unpaired t-test; α1 control grey bar n = 104; KCC2 over black bar n = 121; ***P < 0.001; 
unpaired t-test). (n) somatic immunostaining of immunofluorescence signals for δ subunit in control and KCC2 over-expressing neurons at DIV7. (o) 
Quantification of immunofluorescence signals for δ subunit (control, grey bar n = 17; KCC2 over, black bar n = 42; *P < 0.05; unpaired t-test). scale bar: 
23 µm. Data is presented as mean ± s.e.m.ARTICLE
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with the electrophysiological results obtained in the presence of this 
chloride co-transporter blocker.
a3-1 and d subunits are affected by KCC2 shRNA or DIOA. The 
effects of high [Cl − ]i on the expression of α3-α1 and δ subunits were 
studied in mature neurons either transfected with KCC2 shRNA or 
chronically treated with DIOA (Fig. 1c,d). Gramicidin perforated 
patch-clamp experiments confirmed that, at DIV12, chloride equi-
librium potential (ECl) was  − 57 ± 2.6 mV (Fig. 4a), a value signifi-
cantly more hyperpolarized with respect to DIV6 cultures (Fig. 2c). 
The effectiveness of KCC2 interference on the increase of [Cl − ]i 
on  DIV12  neurons,  was  demonstrated  by  gramicidin  perforated 
patch-clamp experiments in which the chloride equilibrium poten-
tial (ECl) shifted from  − 57 ± 3 to  − 28 ± 1 mV (Fig. 4a–c). In agree-
ment with this result, in immunocytochemistry experiments, KCC2 
levels were reduced in KCC2 shRNA transfected neurons at DIV12   
(Fig. 4d,e). Subsequently, GABAergic sIPSCs were recorded in KCC2 
shRNA transfected neurons from DIV7 to DIV10–13. As previously 
reported, sIPSC decay kinetics accelerated during neuronal matu-
ration9,10 and, interestingly, shRNA transfection slowed down the 
sIPSC relaxation at any developmental stage tested, whereas it did 
not affect sIPSC frequency (Fig. 4f–h). At DIV10–13, the tonic cur-
rent amplitude was also significantly decreased by KCC2 shRNA 
transfection (Fig. 4i). These electrophysiological results were cor-
roborated by immunocytochemistry showing that KCC2 shRNA 
down-regulated the α1 subunit and increased the expression of the 
α3 subunit at DIV12 (Fig. 4j,k), whereas at DIV7 only a moder-
ate decrease of α1 subunit was observed (1469.3 ± 256.6 AU n = 8; 
959.6 ± 93.3 AU n = 23, for control and KCC2 shRNA, respectively; 
P < 0.05;  unpaired  t-test;  not  shown).  Furthermore,  the  surface   
expression  of  the  δ  subunit  was  also  reduced  in  KCC2  shRNA   
transfected neurons at DIV12 (Fig. 4l,m).
In  order  to  increase  the  [Cl − ]i  without  interfering  with  the 
expression level of the KCC2 protein, DIV5 neurons were chroni-
cally  treated  with  the  KCC2  inhibitor  DIOA.  Although  DIOA 
shows only a partial specificity for KCC2 (refs 16,17) this drug 
caused a marked shift of ECl in mature neurons, validating its effect 
in increasing [Cl − ]i ( − 64.96 ± 7.5 and  − 45.05 ± 8.43 mV in con-
trol  and  DIOA  conditions,  respectively;  P < 0.05  unpaired  t-test;   
Fig. 5a–c). Experiments aimed at investigating sIPSCs in the pres-
ence of DIOA showed that, in DIV12–13 cultures, this drug was able 
to induce a slowdown of the sIPSC current relaxation (11.8 ± 0.8 and 
24.4 ± 1.3 ms in control and DIOA conditions, respectively; P < 0.001 
unpaired t-test) (Fig. 5d,e) and significantly decreased the sIPSC 
frequency (Fig. 5f). Chronic treatment with DIOA also decreased 
the tonic current at DIV12–13 (Fig. 5g). In addition, DIOA slightly, 
but  significantly  increased  the  expression  of  α3  subunit,  while   
it markedly decreased the expression of both α1 and δ subunits   
(Fig. 5h–k). Also in this case, electrophysiological data paralleled 
the  immunocytochemistry  results,  indicating  that  differences  in 
phasic and tonic GABAergic currents under conditions of altered 
[Cl − ]i rely on changes in the expression of α3–α1 and δ subunits.
Altogether,  the  similar  effects  of  KCC2  over-expression  and 
down-regulation with respect to Bumetanide and DIOA treatments, 
respectively, indicate that the structural interaction of KCC2 with the 
cytoskeleton plays a minor role in the regulation of α3–α1 and δ  
subunits, and provide a first demonstration that [Cl − ]i itself is res-
ponsible for the regulation of these GABAAR subunits expression.
Zolpidem  and  THIP  revealed  changes  in  a1  and  d  subunits. 
To further demonstrate that modulation of KCC2 protein levels 
affects  the  expression  GABAAR  subunits,  we  used  a  pharmaco-
logical approach exploiting Zolpidem, an allosteric modulator of 
GABAARs that when applied at low concentration preferentially 
enhances  current  mediated  by  α1-containing  receptors18,19,  and 
THIP, a GABAAR agonist, which selectively activates δ-containing 
GABAARs20. As Zolpidem has been reported to selectively prolong 
the decay and increase the peak amplitude of synaptic α1-contain-
ing GABAA receptors18,19, its potentiating effect on synaptic cur-
rents reflects the relative abundance of the α1 subunit in synaptic 
GABAARs. The effect of Zolpidem was studied only on the sIPSC 
decay kinetics, since it has been demonstrated that the amplitude 
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enhancement exerted by this drug critically depends on the extent 
of  postsynaptic  receptor  saturation18.  Spontaneous  GABAergic 
activity was recorded in the presence of Zolpidem (300 nM) in both 
DIV6–7 and DIV12–13 cultures under conditions of altered KCC2 
expression.  At  DIV6–7,  the  increase  of  sIPSC  mean  decay  time 
constant induced by Zolpidem application was significantly higher 
in  KCC2-transfected  cells  with  respect  to  control  (5.0 ± 3.5  and 
18.7 ± 6.8 ms in control and KCC2, respectively; P < 0.05 ANOVA) 
(Fig. 6a). In contrast, the robust Zolpidem-induced relaxation of 
sIPSC decay kinetics was significantly reduced in KCC2-shRNA 
transfected  neurons  (44.6 ± 5.9  and  17.9 ± 4.4 ms  in  control  and 
KCC2 shRNA, respectively; P < 0.01 ANOVA) (Fig. 6a). These data 
suggest that the expression levels of KCC2 affect α1 subunit expres-
sion.  To  directly  test  whether  up-  or  down-regulation  of  KCC2 
also interferes with δ subunit expression we exogenously applied 
both GABA and THIP pulses and, as previously reported, the ratio 
between the current peak amplitude obtained in THIP and GABA 
(ITHIP/IGABA) was taken as a measure of the expression of δ-con-
taining GABAARs9,20. At DIV6–7, KCC2 over-expression signifi-
cantly increased the ITHIP/IGABA ratio (0.05 ± 0.02 and 0.16 ± 0.05 
in control and KCC2 over, respectively; P < 0.001 ANOVA), indicat-
ing an increase in δ-containing GABAARs with respect to control 
(Fig. 6b,c). Conversely, KCC2 shRNA reduced the ITHIP/IGABA ratio 
(0.26 ± 0.05 and 0.05 ± 0.01 in control and KCC2 shRNA, respec-
tively; P < 0.001 ANOVA) indicating that KCC2 down-regulation   
significantly decreased the expression of extrasynaptic tonic receptors   
at mature stages (Fig. 6b,d). Taken together, these results suggest 
that KCC2 expression affects GABAAR subunit composition at the 
level of both α1 (phasic current) and δ (tonic current) subunits.
Chloride  ions  affect  a3 − 1  and  d  subunits  expression.  Early 
GABAergic signaling triggers elevation in the intracellular Ca2 +  
concentration which plays an important trophic role for developing 
networks6,12. To rule out the possibility that the changes in GABAAR 
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subunits expression induced by KCC2 over-expression or down-
regulation are due to trophic alterations resulting from the lack or 
persistence of GABAergic depolarization during neuronal develop-
ment, we investigated the kinetics of GABAergic synaptic currents 
in neurons with altered KCC2 expression which were chronically 
treated with the non-competitive GABAAR antagonist picrotoxin 
(PTX). Similar to the data reported in Figs 2g and 4g, KCC2 over-
expressing  neurons  chronically  treated  with  PTX  showed  faster 
sIPSC  decay  kinetics  (40.41 ± 4.7  and  29.23 ± 1.65 ms  in  control 
and KCC2 over-expression, respectively; P < 0.01 unpaired t-test;   
Fig.  7a,c)  whereas  neurons  expressing  KCC2  shRNA  displayed 
slower sIPSC decay kinetics (26.56 ± 2.3 and 35.13 ± 3.19 in control 
and KCC2 shRNA, respectively; P < 0.05 unpaired t-test; Fig. 7b,c). 
These observations suggest that the effect exerted by [Cl − ]i on the 
α3-α1 and δ GABAAR subunit expression does not depend on the 
trophic support provided by GABAergic signaling.
To further investigate the causal link between changes in [Cl − ]i 
variations and expression of distinct α subunits, KCC2 was down-
regulated in mature neurons (DIV12) (Fig. 1e), when both the shift 
in the polarity of chloride gradient and the α3 to α1 switch had 
already occurred and examined α subunit expression and IPSCs 
characteristics under these conditions. As shown in Fig. 8a,b, sIP-
SCs recorded from DIV14 neurons transfected with KCC2 shRNA 
at DIV12, showed significantly slower decay kinetics with respect to 
control (18.9 ± 1.1 and 28.1 ± 2.5 ms in control and KCC2 shRNA, 
respectively; P < 0.01 unpaired t-test). In line with this observation, 
immunocytochemistry  experiments  showed  that  KCC2  shRNA 
transfection up-regulated the α3 subunit, whereas it considerably 
reduced α1 subunit expression (Fig. 8d,e). In addition, neurons 
with down-regulated levels of KCC2 showed smaller tonic currents 
(Fig. 8c), an observation corroborated by the lower δ immunore-
activity in KCC2 shRNA neurons (Fig. 8d,f). Taken together, these 
data suggest that the α3 to α1 subunit switch and the expression of 
δ subunit strictly correlate with [Cl − ]i, whereas they are independ-
ent of the trophic effect of depolarizing GABA and of the stages of 
neuronal development.
Discussion
Our findings provide evidence for a physiological role of neuronal 
[Cl − ]i, in regulating the expression of various GABAAR subtypes, 
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thereby tuning phasic and tonic GABAergic inhibition independ-
ently of GABAergic signaling. It has been recently demonstrated 
that intracellular chloride ions bind to specific sites in the GABAAR 
pore affecting the receptor gating21,22. Our observations further 
extend the hypothesis that [Cl − ]i acts as a intracellular messenger 
exerting a feedback control on GABAA currents not only by inter-
fering with GABAAR gating, but also by modulating the expression 
of GABAAR subunits. The latter mechanism would therefore repre-
sent an additional level of complexity in the role of neuronal chlo-
ride homeostasis.
A growing body of evidence indicates that chloride is unevenly 
distributed across neuronal sub-compartments, although this issue 
is still a matter of debate and its physiological relevance has not 
been fully elucidated16,23–27. Along this line, it has been recently 
proposed that, in the hippocampus, chloride homeostasis can be 
regulated at the level of individual synapses28. Indeed, perisomatic 
inhibitory synapses formed between parvalbumin positive (PV + ) 
interneurons and CA1 hippocampal pyramidal neurons are selec-
tively  modulated  by  ClC-2,  a  channel  which  extrudes  excess  of 
chloride under conditions of sustained activity. In contrast, CCK +  
interneuron synapses onto CA1 pyramidal neurons, also located 
in the somatic region of CA1 pyramidal neurons, do not show this 
[Cl − ]i regulation. Interestingly, synapses formed by PV +  interneu-
ron onto CA1 pyramidal neurons express α1-containing GABAARs, 
whereas CCK +  interneuron-CA1 synapses express α2-containing 
GABAARs29. Although the actual occurrence of chloride micro-
domains is still a matter of debate, it is tempting to speculate that 
GABAAR subtypes composition could be regulated by [Cl − ]i in a 
synaptic-specific fashion.
In the present study, we found that over-expression of KCC2 
does  not  affect  the  frequency  of  sIPSCs.  These  findings  appear 
counterintuitive, since the early GABA depolarizing action has been 
shown to promote the morphological maturation of the neurons30. 
Nevertheless, the effect of [Cl − ]i reduction at early developmental 
stage on the frequency of spontaneous GABAergic synaptic currents   
observed in previous studies, is controversial31–34. This discrepancy 
could depend on the various approaches used to decrease the [Cl − ]i 
such  as  KCC2  over-expression,  NKCC1  shRNA  or  Bumetanide 
treatment. In addition further variability could be due to the differ-
ent developmental stage at which [Cl − ]i manipulation is performed 
and the neuronal type analyzed. The same considerations could be 
invoked to explain the discrepancy between our results and previ-
ous investigations on the sIPSC frequency in chronic treatment with 
DIOA35.
The  chronic  pharmacological  blockade  of  GABAARs  during 
development has been shown to produce a significant delay of the 
[Cl − ]i shift36. This observation is in agreement with our results 
showing  that  chronic  treatment  with  picrotoxin  (PTX)  induced 
slower sIPSC decay kinetics in DIV12–14 neurons (Fig. 7c), sup-
porting  the  notion  that  [Cl − ]i  regulates  GABAergic  PSC  decay 
kinetics and α subunits expression.
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We observe that the ECl in shRNA KCC2 neurons was consider-
ably shifted toward positive values (Fig. 4c). This could be explained 
by a residual expression of NKCC1 (refs 16,37) and/or by other yet 
unidentified chloride uptake mechanisms.
Our data emphasize the role of [Cl − ]i in regulating the α3-α1 and 
δ subunit expression and therefore the decay kinetics of GABAergic   
PSCs  and  the  tonic  inhibition.  At  this  stage,  however,  it  is  not   
clear whether the dependence of α3-α1 and δ subunit expression 
on  [Cl − ]i  is  due  to  alteration  of  transcription,  translation,  traf-
ficking,  targeting  or  post-transcriptional  modifications  of  such 
GABAAR subunits. In these various scenarios, chloride ions would 
exert their effects either by binding directly to GABAARs and/or 
by acting through GABAAR subunit-interacting-proteins or tran-
scription factors. In addition, altered [Cl − ]i could interfere with 
other mechanisms including intracellular pH (ref. 38) or glutamate 
reuptake39. It has been reported that KCC2 structurally associates 
with the cytoskeleton and participates in controlling spine morphol-
ogy, an effect that does not involve its ionic transport function15. 
KCC2 down-regulation, therefore, would interfere with glutama-
tergic function which, in turn, may alter GABAergic transmission. 
Although this is a plausible possibility, our experiments show that 
modifying  [Cl − ]i  without  interfering  with  the  KCC2  expression 
level, exerts a similar effect on α3-α1 and δ expression with respect 
to KCC2 over-expression and down-regulation.
The majority of neurons analyzed in the present study have been 
classified as stellate/basket cells, based on their morphology and 
immunoreactivity  to  specific  interneuronal  markers  (Methods). 
Although most of the studies characterizing the α3/α1 and δ subu-
nits switch have been carried out in granule cells, we show here that, 
in stellate/basket cells in culture, the developmental expression of 
such subunits appears to be comparable to that observed in gran-
ule cells. Those findings are confirmed by works in both cerebellar 
stellate/basket  interneurons  and  hippocampal  PV +   interneurons 
showing a developmental increase of α1-containing receptors asso-
ciated with increases in KCC2 levels40,41. In keeping with this, our 
model is validated by the fact that, in our experiments, the develop-
mental chloride inversion occurs at the same time of α3/α1 subunit 
switch and δ subunit increase.
Under  physiological  conditions  of  sustained  hyperpolarizing 
GABAergic activity, accumulation of [Cl − ]i would induce smaller 
IPSC peak amplitude by lowering the driving force of the chlo-
ride current. It can be speculated that, in these scenario, slower   
GABAergic currents would homeostatically regulate the amount 
of GABAergic charge transfer by prolonging the IPSC duration. 
Conversely, under pathologic conditions, in which the increase of 
[Cl − ]i may lead to depolarizing actions42–44, the IPSCs slow-down 
together with the lower shunting inhibition due to the reduced tonic 
GABAA conductance could contribute in determining an enhance-
ment of the aberrant excitatory GABA action.
Methods
CGC cell culture and chronic treatment. All the experiments involving mice were 
performed in accordance with Italian Ministry of Health. Primary cultures of cer-
ebellar granule cells (CGCs) were prepared from cerebella of postnatal day 7 mice. 
After decapitation of the pups, we collected cerebella and subsequently we removed 
the meninges, as well as any large blood vessels or extraneous brain regions that 
are stuck to the cerebella. We chopped the tissue finely in 2 directions and then 
we centrifuge at 1,000 r.p.m. for 2 min. Tissue were dissociated with 0.25 mg/ml 
trypsin (Invitrogen, Italy) for 15 min at 37 °C in water bath and gently swirl the 
cerebella every 5 min. After dissociation of the cells, CGCs were plated in 12 well 
dishes at a density of 1×106 cells/ml on glass coverslips coated with poly-d-lysine 
(0.1 µg/ml) (Sigma, Italy). Cells were cultured in basal Eagle’s medium supple-
mented with 10% fetal bovine serum, 2 mM glutamine, and 100 µg/ml gentamycin 
(Invitrogen, Italy) and maintained at 37 °C in 5% CO2. The final concentration of 
KCl in the culture medium was adjusted to 25 mM (high K + ). Four days after plat-
ing, to achieve functional synapse formation, the medium was replaced with low 
(5 mM) K +  medium (MEM, Invitrogen, Italy) supplemented with 5 mg/ml glucose, 
0.1 mg/ml transferrin, 0.025 mg/ml insulin, 2 mM glutamine, 20 µg/ml gentamicin. 
5 µM cytosine arabinofuranoside (Sigma, Italy) was added to all cultures to inhibit 
glial proliferation. Control (pRNAT-U6.3-cGFP) and KCC2 RNA interference 
(KCC2 shRNA) vectors were transfected into neurons at 5 days in vitro (DIV5) or 
DIV12 using Effectene reagent according to the manufacturer’s recommendations 
(Qiagen, Valencia, CA, USA). Nucleofection of CGCs with control (pCAG-IRES- 
tdTomato) and KCC2 over-expressing (pCAG-KCC2IRES-tdTomato)30 was 
performed at DIV0 following the manufacturer’s protocol (Amaxa, Gaithersburg, 
MD). CGCs cultures represent a mixed neuronal population mainly composed 
by granule cells and stellate/basket interneurons. In the attempt to assess whether 
transfection occurred preferentially in one of these two neuronal subtypes, we 
studied the soma area of the GFP- or td-Tomato-transfected neurons as the size 
of granule cells is markedly smaller than that of stellate/basket interneurons. The 
distribution of the soma diameter of transfected cells was clearly bimodal and 
peaked at ~8 and 12 µm. Interestingly, the distribution of non-transfected cells 
corresponded to the lower peak of the aforementioned distribution. The cell size 
relative to the peaks of the bimodal distribution was similar to the values reported 
for granule cells and stellate/basket cell, respectively9,45. The formal fit of the 
bimodal distribution indicated that the relative component of granule cells versus 
interneurons was ~0.3. Immunocytochemistry experiments where GABAergic 
interneurons were stained with anti-GAD65 antibody confirmed this estimation 
(data not shown). This suggests that interneurons represented the major popula-
tion of GFP- or td-Tomato-transfected neurons. Chronic treatments with PTX 
(100 µM, Sigma, Italy) and R-( + )-[(dihydroindenyl)oxy] (DIOA) (10 µM, Sigma, 
Italy) were started at DIV5 in control and in KCC2 shRNA transfected neurons. 
The same treatment with PTX and Bumetanide (30 µM, Sigma, Italy) were started 
the day of plating (DIV0) in control and KCC2 over-expressing neurons.
Plasmid constructs. A small hairpin RNA plasmid interfering with the expression 
of KCC2 (KCC2 shRNA), was designed using the GenScript target finder. Two 
complementary annealed oligonucleotides (Top oligo 5′-GGATCCCGTAAG 
TGGTACAGAAACGTGGTTTGATATCCGACCACGTTTCTGTACCACT 
TATTTTTTCCAAA-3′; Bottom oligo 5′-AAGCTTTTGGAAAAAATAAGTGG 
TACAGAAACGTGGTCGGATATCAAACCACGTTTCTGTACCACTTACGG-3′) 
targeting a 21-nucleotide stretch in KCC2 were inserted between the BamHI and 
HindIII sites of the pRNAT-U6.3-cGFP vector (GenScript) to generate the KCC2 
shRNA construct. A non-silencing control shRNA vector was engineered identi-
cally, except that the KCC2 target sequence was substituted by a 21-nucleotides 
sequence (5′-AATTCTCCGAACGTGTCACGT-3′) bearing no significant homol-
ogy to any mammalian gene. The identity of both shRNA constructs were verified 
by sequencing.
Immunocytochemistry and epifluorescence microscopy. Surface live immunola-
beling of α1, α3 and δ subunits was performed by incubating cultured neurons with 
the appropriate antibody for 10 min (α1—1:300 and α3—1:200) (Alomone, Israel) 
(δ—1:100) (a gift of Professor W. Sieghart, Medical University of Vienna, Austria). 
After washing in phosphate-buffered saline (PBS) (Invitrogen, Italy), neurons were 
fixed in 4% paraformaldehyde - 4% sucrose and then blocked in PBS containing 10% 
horse serum and 0.5% bovine serum albumin. For immunostaining of KCC2, VGAT 
and GAD65 cells were permeabilized with 0.1% Triton X-100 for 10 min in blocking 
solution and incubated with anti-KCC2 primary antibody (1:100, Millipore), VGAT 
primary antibody (1:400, Synaptic Systems, Germany) or GAD65 primary antibody 
(1:100) for 1 h at room temperature. Alexa568- and Alexa488-conjugated anti-rabbit 
secondary antibodies (Molecular Probes, Invitrogen, Italy) were used at 1:500 and 
incubated for 30 min at room temperature. Coverslips were mounted in DAKO  
fluorescence mounting medium and observed using a 60× objective (1.4 NA) on 
a wide field inverted fluorescence microscope (Nikon Eclipse Ti). Samples were 
illuminated with a mercury lamp and appropriate filter cubes (Semrock, Italy) for 
Alexa568 and Alexa488 fluorescence. Images were acquired with a digital camera 
(Hamamatsu EM-CCD C9100) using MetaMorph 7.5 (Molecular Devices). The 
same software was also used for quantitative analysis of acquired images. The 
analysis was restricted to the soma of transfected neurons identified by fluores-
cence-tagged recombinant proteins (EGFP or td-Tomato). Receptor quantity was 
calculated as the integrated fluorescence intensity measured on the soma, divided 
by its area. Background fluorescence was subtracted from all images before analysis. 
Control experiments without the primary antibodies were performed to test fluores-
cence signal arising from non specific binding of secondary antibodies.
Electrophysiology recordings. Spontaneous inhibitory postsynaptic currents 
(sIPSCs) were recorded from 6 to 14 DIV neurons in the whole-cell voltage clamp 
configuration at room temperature and holding potential of  − 60 mV, using the 
700B Axopatch amplifier (Molecular Devices, Sunnyvale, CA). Patch pipettes were 
pulled from borosilicate glass capillaries and displayed resistance ~5–10 MΩ when 
filled with high chloride intracellular solution containing (in mM): 122 CsCl; 
2 MgCl2; 2 CaCl2; 4 Na2ATP; 11 BAPTA; 10 HEPES; (300 mOsm and pH 7.2). 
Extracellular solution contained (in mM): 145 NaCl, 2 KCl, 2 MgCl2, 2 CaCl2, 10 
HEPES, 10 glucose, and 10 µM d-serine, adjusted to pH 7.4 with NaOH. sIPSCs 
detection was performed using the sliding template method of the Clampfit 10.1 
software (Molecular Devices, Sunnyvale, CA). Traces were acquired at 50 KHz, 
filtered off-line at 1 KHz using the Clampfit Bessel digital filter. On the average, 
three hundred events were collected for each recorded cell. Double events were ARTICLE     
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rejected from analysis of kinetics and amplitude. Events were aligned at 20% of 
the 10–90% rise time and the current decay was fitted according to the func-
tion: y(t) = ΣAiexp( − t/τi), where Ai are the fractions of respective components 
(ΣAi = 1) and τi are the time constants. The weighted deactivation time constant 
was calculated using the formula τw = ΣτiAi. Gramicidin perforated patch experi-
ments were used to measure the chloride equilibrium potential (ECl). Intracellular 
solution contained (in mM): 150 KCl; 2 MgCl2; 2 CaCl2; 4 Na2ATP; 11 BAPTA; 
10 HEPES (300 mOsm and pH 7.2). Gramicidin was added to the intracellular 
solution at a final concentration of 80 µg/ml from a stock 10 mg/ml in DMSO. The 
tip of the patch pipette was filled with normal intracellular solution, while the rest 
of the pipette contained the gramicidin-containing solution. Currents were evoked 
by puff-applying isoguvacine (10 µM) to the neuron soma through a micropipette 
coupled to an electrically gated pressure valve (Picospritzer III, Parker, Cleveland, 
OH, USA) at pulse duration of 50 ms and pressure 20 kPa. The holding poten-
tial was increased at 10 mV steps. ECl −  was determined as the x-axis intercepts 
point of the resulting I–V curve. Tonic current amplitudes were measured as the 
baseline-shift induced by the bath application of the GABAAR antagonist bicucul-
line methobromide (10 µM). The values of baseline current in control and in 
bicuculline were calculated by Gaussian fit of the component relative to the white 
noise of the all-point histogram relative to 5–10 s trace portions46. Only recordings 
exhibiting stable baseline were included in the analysis. GABA (application of a 
saturating concentration at 1 mM to estimate the total function of GABAARs) and 
4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol (THIP) (30 µM) were prepared in 
water and diluted to the desired concentration in extracellular solution. Both drugs 
were locally applied through Picospritzer as above. The ratio of THIP to GABA 
was calculated as the average of THIP current densities normalized to the average 
of currents densities elicited by GABA. Zolpidem, (a gift of Professor G. Bonanno, 
University of Genoa, Italy) a preferential modulator of α1-contaning GABAARs, 
was dissolved in water in stock solution (3 mM) and diluted to the concentration of 
300 nM in extracellular solution for bath application.
Statistical analysis. Values are expressed as means ± s.e.m. (standard error of 
the mean) throughout. Unless otherwise stated, statistical analysis was performed 
using the paired or unpaired Student’s t-tests to compare two experimental groups 
and ANOVA followed by the Tukey’s multiple comparison test when more than 
two experimental groups were analyzed. Statistical significance was abbreviated as 
follows: *P < 0.05, **P < 0.01, ***P < 0.001. 
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